<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Imipenem, cilastatin, and relebactam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Imipenem, cilastatin, and relebactam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Imipenem, cilastatin, and relebactam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="121954" href="/d/html/121954.html" rel="external">see "Imipenem, cilastatin, and relebactam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53989752"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Recarbrio</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53401703"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Carbapenem;</li>
<li>
                        Beta-Lactamase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F53477782"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Doses are expressed as the combined amount of imipenem, cilastatin, and relebactam.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Not recommended for routine empiric use.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with or at risk for extensively drug-resistant pathogens (nonsusceptible to ≥1 agent in all but 2 or fewer antimicrobial classes) (eg, carbapenem-resistant Enterobacterales) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-Quale.1','lexi-content-ref-33177185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-Quale.1','lexi-content-ref-33177185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.25 g every 6 hours. Total duration of therapy is 4 to 7 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20163262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20163262'])">Ref</a></span>); for infections managed without surgical or percutaneous intervention, a longer duration may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-</b>
<b>acquired or ventilator-associated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with or at risk for extensively drug-resistant pathogens (nonsusceptible to ≥1 agent in all but 2 or fewer antimicrobial classes) (eg, carbapenem-resistant Enterobacterales) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-Quale.1','lexi-content-ref-33177185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-Quale.1','lexi-content-ref-33177185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> IV:</b> 1.25 g every 6 hours. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days, but a longer course may be required for severe or complicated infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with or at risk for extensively drug-resistant pathogens (nonsusceptible to ≥1 agent in all but 2 or fewer antimicrobial classes) (eg, carbapenem-resistant Enterobacterales) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-Quale.1','lexi-content-ref-33177185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35439291','lexi-content-ref-21793988','lexi-content-ref-Quale.1','lexi-content-ref-33177185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.25 g every 6 hours. Switch to an appropriate oral regimen once symptoms improve, if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooton.1','lexi-content-ref-35439291','lexi-content-ref-31400759','lexi-content-ref-28575389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooton.1','lexi-content-ref-35439291','lexi-content-ref-31400759','lexi-content-ref-28575389'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53477784"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Estimation of renal function for the purpose of dosage adjustment should be done using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥90 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 60 to 89 mL/minute: 1 g (imipenem 400 mg/cilastatin 400 mg/relebactam 200 mg) every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 59 mL/minute: 750 mg (imipenem 300 mg/cilastatin 300 mg/relebactam 150 mg) every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to 29 mL/minute: 500 mg (imipenem 200 mg/cilastatin 200 mg/relebactam 100 mg) every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34704389','lexi-content-ref-36880088','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: The manufacturer’s labeling recommends against use in patients not receiving or scheduled to receive hemodialysis. In the absence of data, 500 mg (imipenem 200 mg/cilastatin 200 mg/relebactam 100 mg) every 12 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b>
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35906810','lexi-content-ref-36880088']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35906810','lexi-content-ref-36880088'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (imipenem [55%], cilastatin [63%], and relebactam [unknown]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1929334','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1929334','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg (imipenem 200 mg/cilastatin 200 mg/relebactam 100 mg) every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Not recommended in manufacturer’s labeling (has not been studied). In the absence of data, may consider 500 mg (imipenem 200 mg/cilastatin 200 mg/relebactam 100 mg) every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">Very limited information available; removal likely based on in vitro data and simulations of CRRT conditions with the 3-drug combination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34680765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34680765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) as a single dose, followed by 750 mg (imipenem 300 mg/cilastatin 300 mg/relebactam 150 mg) every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">No information available; some removal likely based on drug characteristics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>), followed by:</p>
<p style="text-indent:-2em;margin-left:6em;">PIRRT days: 750 mg every 8 hours <b>or</b> 750 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-PIRRT days: 500 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F53477785"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatic impairment is not likely to have any effect on exposure.</p></div>
<div class="block doe drugH1Div" id="F53477783"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53529442"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (8%), hyponatremia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (4%), diarrhea (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: <i>Clostridioides difficile</i> associated diarrhea</p></div>
<div class="block coi drugH1Div" id="F53401706"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Severe hypersensitivity (eg, anaphylaxis) to cilastatin, imipenem, relebactam, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53477768"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions, history of seizures) and adjust dose in renal impairment to avoid drug accumulation. Drug accumulation may increase seizure risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity/anaphylactic reactions, some fatal, have been reported with beta-lactams. Carefully inquire about previous hypersensitivity reactions to penicillins, carbapenems, cephalosporins, other beta-lactams, and other allergens. Discontinue treatment and institute supportive care if a hypersensitivity reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD); CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. Increased seizure risk has been reported in patients with significant renal dysfunction. Do not use in patients with CrCl ≤15 mL/minute unless hemodialysis is instituted within 48 hours.</p></div>
<div class="block foc drugH1Div" id="F53989753"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Recarbrio: Imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F53989751"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54082348"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Recarbrio Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 g (per each): $368.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F53477786"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 30 minutes.</p></div>
<div class="block use drugH1Div" id="F53401705"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b> Treatment of complicated intra-abdominal infections in patients ≥18 years of age with limited or no alternative options caused by the following susceptible gram-negative microorganisms: <i>Bacteroides cacace</i>, <i>Bacteroides fragilis</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, <i>Bacteroides uniformis</i>, <i>Bacteroides vulgatus</i>, <i>Bifidobacterium stercoris</i>, <i>Citrobacter freundii</i>, <i>Enterobacter cloacae</i>, <i>Escherichia coli</i>, <i>Fusobacterium nucleatum</i>, <i>Klebsiella aerogenes</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Parabacteroides distasonis</i>, and <i>Pseudomonas aeruginosa</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital </b>
<b>acquired or ventilator associated:</b> Treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients ≥18 years of age caused by the following susceptible gram-negative microorganisms: <i>Acinetobacter calcoaceticus-baumannii </i>complex, <i>E. cloacae</i>, <i>E. coli</i>, <i>Haemophilus influenzae,</i>
<i>K. aerogenes</i>, <i>K. oxytoca</i>, <i>K. pneumoniae</i>, <i>P. aeruginosa, </i>and<i> Serratia marcescens.</i></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b> Treatment of complicated urinary tract infections, including pyelonephritis, in patients ≥18 years of age with limited or no alternative options caused by the following susceptible gram-negative microorganisms: <i>E. cloacae</i>, <i>E. coli</i>, <i>K. aerogenes</i>, <i>K. pneumoniae</i>, and <i>P. aeruginosa.</i></p></div>
<div class="block cyt drugH1Div" id="F53490910"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F53490907"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Imipenem may enhance the neurotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased. Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Imipenem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F53477764"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Imipenem and cilastatin cross the placenta (Cho 1988; Heikkilä 1992). Information specific to relebactam has not been located.</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the imipenem/cilastatin monograph for additional information.</p></div>
<div class="block brc drugH1Div" id="F53477767"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Imipenem is present in breast milk (Chung 2002; Ito 1988). Excretion of relebactam is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to the imipenem/cilastatin monograph for additional information.</p></div>
<div class="block mop drugH1Div" id="F53477788"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic renal function tests; signs of hypersensitivity/anaphylaxis.</p></div>
<div class="block pha drugH1Div" id="F53477773"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Imipenem: Binds to PBP 2 and PBP 1B in Enterobacteriaceae and <i>P. aeruginosa</i> and subsequently inhibits penicillin-binding proteins, leading to the disruption of bacterial cell wall synthesis.</p>
<p style="text-indent:-2em;margin-left:2em;">Cilastatin: Renal dehydropeptidase inhibitor that limits renal metabolism of imipenem.</p>
<p style="text-indent:-2em;margin-left:2em;">Relebactam: Beta-lactamase inhibitor that protects imipenem from degradation by certain serine beta-lactamases (eg, Sulhydryl Variable, Temoneira, Cefotaximase-Munich, <i>E. cloacae</i> P99, Pseudomonas-derived cephalosporinase, and Klebsiella-pneumoniae carbapenemase).</p></div>
<div class="block phk drugH1Div" id="F53477774"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Imipenem: 24.3 L; cilastatin: 13.8 L; relebactam: 19 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Imipenem: ~20%; cilastatin: ~40%; relebactam: ~22%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Imipenem is metabolized in the kidney by dehydropeptidase I; cilastatin prevents imipenem metabolism by this enzyme. Relebactam is minimally metabolized.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Imipenem: 1 hour; relebactam: 1.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as unchanged drug: imipenem: ~63%; cilastatin: ~77%; relebactam: &gt;90%).</p></div>
<div class="block phksp drugH1Div" id="F53477780"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC is increased in patients with CrCl 15 to 89 mL/minute (imipenem: 1.1 to 2.6-fold; cilastatin: 1.2 to 5.5-fold; relebactam: 1.2 to 4.7-fold).</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Imipenem and cilastatin (in combination with relebactam):</p>
<p style="text-indent:-2em;margin-left:8em;">Interrelationship between imipenem and cilastatin exposure, relebactam exposure, minimum inhibitory concentration (MIC), and efficacy is not fully elucidated; efficacy is time dependent (see Imipenem and Cilastatin monograph), but MIC changes with changing relebactam concentrations (MIC<sub>dynamic</sub>). Maximal efficacy was achieved at <i>f</i>T &gt; MIC<sub>dynamic </sub>&gt;40% to 50% (Bhagunde 2012; Wu 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">Relebactam (in combination with imipenem and cilastatin):</p>
<p style="text-indent:-2em;margin-left:8em;">AUC, associated with free 24-hour AUC (<i>f</i>AUC<sub>24</sub>) of relebactam to imipenem and cilastatin-relebactam MIC ratio.</p>
<p style="text-indent:-2em;margin-left:10em;">Gram negative organisms (including <i>P. aeruginosa</i>): Goal: 2.7 (bacteriostasis), 4.7 (1-log kill), 7.5 (2-log kill) (Bhagunde 2019a; Bhagunde 2019b; Mavridou 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Imipenem and cilastatin: See Imipenem and Cilastatin monograph.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> Imipenem and cilastatin: See Imipenem and Cilastatin monograph.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54492098"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Recarbrio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22330927">
<a name="22330927"></a>Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors. <i>Antimicrob Agents Chemother</i>. 2012;56(5):2237-2240. doi:10.1128/AAC.06113-11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/22330927/pubmed" id="22330927" target="_blank">22330927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31508899">
<a name="31508899"></a>Bhagunde P, Patel P, Lala M, et al. Population pharmacokinetic analysis for imipenem-relebactam in healthy volunteers and patients with bacterial infections. <i>CPT Pharmacometrics Syst Pharmacol.</i> 2019a;8(10):748-758. doi:10.1002/psp4.12462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/31508899/pubmed" id="31508899" target="_blank">31508899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479762">
<a name="31479762"></a>Bhagunde P, Zhang Z, Racine F, et al. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. <i>Int J Infect Dis.</i> 2019b;89:55-61. doi:10.1016/j.ijid.2019.08.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/31479762/pubmed" id="31479762" target="_blank">31479762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3062206">
<a name="3062206"></a>Cho N, Fukunaga K, Kunii K, Kobayashi I, Tezuka K. Studies on imipenem/cilastatin sodium in the perinatal period [in Japanese]. <i>Jpn J Antibiot</i>. 1988;41(11):1758-1773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/3062206/pubmed" id="3062206" target="_blank">3062206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837. doi:10.2165/00128072-200204120-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35906810">
<a name="35906810"></a>Fratoni AJ, Mah JW, Nicolau DP, Kuti JL. Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance. <i>J Antimicrob Chemother</i>. 2022;77(11):2992-2999. doi:10.1093/jac/dkac261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/35906810/pubmed" id="35906810" target="_blank">35906810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1482132">
<a name="1482132"></a>Heikkilä A, Renkonen OV, Erkkola R. Pharmacokinetics and transplacental passage of imipenem during pregnancy. <i>Antimicrob Agents Chemother</i>. 1992;36(12):2652-2655. doi:10.1128/aac.36.12.2652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/1482132/pubmed" id="1482132" target="_blank">1482132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.1">
<a name="Hooton.1"></a>Hooton, TM. Acute complicated urinary tract infection (including pyelonephritis) in adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3210308">
<a name="3210308"></a>Ito K, Izumi K, Takagi H, Tamaya T, Hayasaki M. Fundamental and clinical evaluation of imipenem/cilastatin sodium in the perinatal period [in Japanese]. <i>Jpn J Antibiot</i>. 1988;41(11):1778-1785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/3210308/pubmed" id="3210308" target="_blank">3210308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34680765">
<a name="34680765"></a>Jang SM, Yessayan L, Dean M, Costello G, Katwaru R, Mueller BA. Imipenem/Relebactam ex vivo clearance during continuous renal replacement therapy. <i>Antibiotics (Basel)</i>. 2021;10(10):1184. doi:10.3390/antibiotics10101184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/34680765/pubmed" id="34680765" target="_blank">34680765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1929334">
<a name="1929334"></a>Konishi K, Suzuki H, Saruta T, et al. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. <i>Antimicrob Agents Chemother</i>. 1991;35(8):1616-1620. doi:10.1128/AAC.35.8.1616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/1929334/pubmed" id="1929334" target="_blank">1929334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21793988">
<a name="21793988"></a>Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. <i>Clin Microbiol Infect</i>. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/21793988/pubmed" id="21793988" target="_blank">21793988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25403667">
<a name="25403667"></a>Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. <i>Antimicrob Agents Chemother.</i> 2015;59(2):790-795. doi:10.1128/AAC.03706-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/25403667/pubmed" id="25403667" target="_blank">25403667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31400759">
<a name="31400759"></a>Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1:a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. <i>Clin Infect Dis</i>. 2020;70(9):1799-1808. doi:10.1093/cid/ciz530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/31400759/pubmed" id="31400759" target="_blank">31400759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34704389">
<a name="34704389"></a>Patel M, Bellanti F, Daryani NM, et al. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia. <i>Clin Transl Sci</i>. 2022;15(2):396-408. doi:10.1111/cts.13158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/34704389/pubmed" id="34704389" target="_blank">34704389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: Medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quale.1">
<a name="Quale.1"></a>Quale J, Spelman D. Overview of carbapenemase-producing gram-negative bacilli. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Recarbrio.1">
<a name="Recarbrio.1"></a>Recarbrio (imipenem/cilastatin/relebactam) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis</i>. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36880088">
<a name="36880088"></a>Roberts JA, Nicolau DP, Martin-Loeches I, et al. Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. <i>JAC Antimicrob Resist</i>. 2023;5(2):dlad011. doi:10.1093/jacamr/dlad011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/36880088/pubmed" id="36880088" target="_blank">36880088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28575389">
<a name="28575389"></a>Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. <i>J Antimicrob Chemother</i>. 2017;72(9):2616-2626. doi:10.1093/jac/dkx139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/28575389/pubmed" id="28575389" target="_blank">28575389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20163262">
<a name="20163262"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Surg Infect (Larchmt)</i>. 2010;11(1):79-109. doi:10.1089/sur.2009.9930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/20163262/pubmed" id="20163262" target="_blank">20163262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35439291">
<a name="35439291"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). <i>Clin Infect Dis</i>. 2022;75(2):187-212. doi:10.1093/cid/ciac268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/35439291/pubmed" id="35439291" target="_blank">35439291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29507068">
<a name="29507068"></a>Wu J, Racine F, Wismer MK, et al. Exploring the pharmacokinetic/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a Hollow-Fiber infection model. <i>Antimicrob Agents Chemother.</i> 2018;62(5):e02323-17. doi:10.1128/AAC.02323-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/29507068/pubmed" id="29507068" target="_blank">29507068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33177185">
<a name="33177185"></a>Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. <i>Clin Microbiol Rev</i>. 2020;34(1):e00115-e00120. doi:10.1128/CMR.00115-20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imipenem-cilastatin-and-relebactam-drug-information/abstract-text/33177185/pubmed" id="33177185" target="_blank">33177185</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 121885 Version 61.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
